INTRODUCTION AND OBJECTIVES:
The modified Glasgow prognostic score (mGPS) has shown prognostic significance in many malignancies. However, its prognostic value in metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear. Thus, we aimed to evaluate the prognostic value of mGPS in mHSPC patients.
METHODS: From January 2004 to February 2014, 1209 patients were newly diagnosed with prostate cancer at our institute. The subjects were 93 patients with metastatic lesions at diagnosis. The mGPS was estimated based on C-reactive protein (CRP) and albumin levels (score: 2, CRP>1.0 mg/dL and albumin<3.5 gd/L; score 1, CRP>1.0 mg/dL; score 0, CRP>1.0 mg/dL). The impact of mGPS on time to castration-resistant prostate cancer (TTCRPC), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) was analyzed using the Kaplan-Meier method and Cox proportional hazard model. RESULTS: The patients 0 median age was 74 years; and median prostate-specific antigen (PSA) level, 124.3 ng/ml. The Gleason score was 5 or 6 in 8 patients (9%), 7 in 20 (22%), and 8-10 in 65 (70%). We noted node and bone metastases in 54 (58%) and 45 patients (48%), respectively. Four patients had visceral metastases at diagnosis. The mGPS was 0 in 71 (76%), 1 in 16 (17%), and 2 in 6 (6%) mHSPC patients. Patients with higher mGPS had significantly inferior PFS, CSS, and OS (median PFS: 58.0, 22.5, and 21.4 months for scores of 0, 1, and 2, respectively, p<0.0074; CSS: 82.3, 47.1, and 13.6 months, respectively, p<0.0001; and OS: 75.6, 43.7, and 10.3 months, respectively, p<0.0001). In the multivariate analysis, higher mGPS was an independent predictive factor of shorter PFS (p¼0.027), CSS (p¼0.0022), and OS (p¼0.0003).
CONCLUSIONS: Our study demonstrates the prognostic value of the mGPS in mHSPC patients.
